Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Spiegel, C. Brunner, D. Ermini-Fünfschilling, A. Monsch, M. Notter, J. Puxty, L. Tremmel (1991)
A New Behavioral Assessment Scale for Geriatric Out‐ and In‐Patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients)Journal of the American Geriatrics Society, 39
W. Rosen, R. Terry, P. Fuld, R. Katzman, A. Peck (1980)
Pathological verification of ischemic score in differentiation of dementiasAnnals of Neurology, 7
Shi Li, M. Mallory, M. Alford, E. Masliah (1997)
Glutamate Transporter Alterations in Alzheimer Disease Are Possibly Associated with Abnormal APP ExpressionJournal of Neuropathology and Experimental Neurology, 56
W. Zajaczkowski, G. Quack, Wojciech Danysz (1996)
Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion.European journal of pharmacology, 296 3
Werner Herrmann, Kurt Stephan (1992)
Moving from the Question of Efficacy to the Question of Therapeutic Relevance: An Exploratory Reanalysis of a Controlled Clinical Study of 130 Inpatients With Dementia Syndrome Taking PiracetamInternational Psychogeriatrics, 4
Görtelmeyer Görtelmeyer, Erbler Erbler (1992)
Memantine in treatment of mild to moderate dementia syndromeDrug Res, 42
M. Folstein, M. Folstein, S. Folstein, S. Folstein, P. McHugh, P. McHugh (1975)
“Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 12
(1980)
Gemeinsames Papier der das Bundesgesundheitsamt beratenden Zulassungskommission fuÈ r neue Stoe (Kommission A) und der Aufbereitungskommission``Neurologie, Psychiatrie'' (Kommission B3)
Ditzler Ditzler (1991)
Efficacy and tolerability of Memantine in patients with dementia syndrome. A double‐blind, placebo‐controlled trialArzneimittel‐Forschung Drug Res., 41
L. Souren, E. Franssen, B. Reisberg (1995)
Contractures and Loss of Function in Patients with Alzheimer's DiseaseJournal of the American Geriatrics Society, 43
Bundesgesundheitsblatt, 7
(1992)
Methodologische UÈ berlegungen zur Betimmung von Therapierespondern in Nootropikastudien
B. Reisberg, S. Ferris, M. Leon, T. Crook (1982)
The Global Deterioration Scale for assessment of primary degenerative dementia.The American journal of psychiatry, 139 9
(1997)
Note for Guidance on Medicinal Products in the Treatment of Alzheimer’s Disease
C. Parsons, R. Gruner, Jouri Rozental, J. Millar, D. Lodge (1993)
Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)Neuropharmacology, 32
(1987)
Nootropic drugs. E(cid:128)ects and therapeutic e(cid:129)cacy. A phase II study with piracetam as a model
R. Görtelmeyer, H. Erbler (1992)
Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.Arzneimittel-Forschung, 42 7
P. Kam, B. Hoeksma (1989)
[The usefulness of BOP and SIVIS (ADL and behavior rating scales) for the estimation of workload in a psychogeriatric nursing home. Results of a time-standard study].Tijdschrift voor gerontologie en geriatrie, 20 4
T. Zetzsche, K. Baimbridge, H. Möhler, V. Chan‐Palay, B. Regland, V. Chan‐Palay, L. Minthon, L. Edvinsson, R. Ekman, L. Gustafson, K. Urakami, Kazuro Takahashi, Y. Adachi, E. Matsushima, K. Sano, H. Saito, L. Abrahamsson, C. Gottfries, E. Magnus, A. Wettstein, Walter Lang, E. Englund, A. Brun, L. Svennerholm (1990)
Recommendations for Clinical Drug Trials in DementiaDementia and Geriatric Cognitive Disorders, 1
(1988)
Wirkungen und wirksamkeit von nootropica (E(cid:128)ects and e(cid:129)cacy of notropics)
W. Zajaczkowski, T. Frankiewicz, C. Parsons, W. Danysz (1997)
Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTPNeuropharmacology, 36
Reisberg Reisberg, Ferris Ferris, de Leon de Leon, Crook Crook (1982)
The global deterioration scale (GDS): an instrument for the assessment of primary degenerative dementia (PDD)Am. J. Psychiat, 139
(1986)
028 CGI . Clinical Global Impressions
Herrmann Herrmann, Kern Kern (1987)
Nootropic drugs. Effects and therapeutic efficacy. A phase II study with piracetam as a modelNervenarzt, 58
J. Kornhuber, J. Bormann, W. Retz, Marianne Hübers, P. Riederer (1989)
Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex.European journal of pharmacology, 166 3
A. Palmer, S. Gershon (1990)
Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?The FASEB Journal, 4
J. Bormann (1989)
Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels.European journal of pharmacology, 166 3
Parsons Parsons, Gruner Gruner, Rosental Rosental, Millar Millar, Lodge Lodge (1993)
Patch clamp studies on the kinetics and selectivity of N‐methyl‐D‐aspartate receptor antagonism by Memantine (1‐amino‐3.5‐dimethyl‐adamantan)Neuropharmacology, 32
(1980)
Gedragsobservaties , psychologisch oderzoek en overleving na een jaar bij psychogeriatrische patienten
M. Hamilton (1960)
A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 23
(1993)
Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under Memantine treatment
(1989)
Memantine in organic brain syndrome
(1998)
Scale properties of the D-scale in severe dementia
Diesfeldt Hf (1980)
[Observations on behavior, psychological study and 1-year survival in psychogeriatric patients]., 11
(1990)
Veranderingen in hulpbehoevendheld bij patienten in eenpsychogeriatrisch verpleeghuis, bi eerst opname enop peildata
(1971)
Beoordelingsschaal voor oudere patienten (BOP)
W. Herrmann, E. Schärer (1988)
Wirkungen und Wirksamkeit von Nootropika
Marcin Misztal, T. Frankiewicz, C. Parsons, Wojciech Danysz (1996)
Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine.European journal of pharmacology, 296 1
(1987)
Diagnostic and Statistical Manual of Mental Disorders, DSM-III-R
L. Ferm (1974)
Behavioural Activities in Demented Geriatric Patients, 16
W. Müller, E. Mutschler, P. Riederer (1995)
Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's DementiaPharmacopsychiatry, 28
P. Francis, N. Sims, A. Procter, D. Bowen (1993)
Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic PerspectivesJournal of Neurochemistry, 60
W. Herrmann, U. Kern (1987)
[Nootropic drugs: effects and effectiveness. A reflection exemplified by a phase III study using piracetam].Der Nervenarzt, 58 6
J. Greenamyre, W. Maragos, R. Albin, J. Penney, A. Young (1988)
Glutamate transmission and toxicity in alzheimer's diseaseProgress in Neuro-Psychopharmacology and Biological Psychiatry, 12
E. Franssen, B. Reisberg, A. Kluger, E. Sinaiko, Conrado Boja (1991)
Cognition-independent neurologic symptoms in normal aging and probable Alzheimer's disease.Archives of neurology, 48 2
G. Wenk, W. Danysz, D. Roice (1996)
The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis.Neuroreport, 7 9
Objectives To assess clinical efficacy and safety of memantine—an uncompetitive N‐methyl‐d‐aspartate (NMDA) antagonist—in moderately severe to severe primary dementia. Materials and methods Dementia was defined by DSM‐III‐R criteria and severity was assessed by the Global Deterioration Scale (stages 5–7) and the Mini‐Mental State Examination (<10 points). Primary endpoints were the Clinical Global Impression of Change (CGI‐C) rated by the physician, and the Behavioural Rating Scale for Geriatric Patients (BGP), subscore ‘care dependence’, rated by the nursing staff. Secondary endpoints included the modified D‐Scale (Arnold/Ferm). Results The ITT sample comprised 166 patients and 151 patients were treated per protocol. At 12‐week ITT endpoint analysis, 82 received memantine 10 mg per day, 84 placebo. Dementia was in 49% of the Alzheimer type and in 51% of the vascular type (CT, Hachinski score). A positive response in the CGI‐C was seen in 73% versus 45% in favour of memantine (stratified Wilcoxon p<0.001), independent of the etiology of dementia. The results in the BGP subscore ‘care dependence’ were 3.1 points improvement under memantine and 1.1 points under placebo (p=0.016). A coincident response of the two independent target variables was observed in 61.3% (memantine) versus 31.6% (placebo). Secondary endpoint analysis of the D‐Scale assessing basic ADL functions support the primary results. Regarding the safety profile, no significant differences between treatment groups were observed. Conclusions The results of this trial support the hypothesis that memantine treatment leads to functional improvement and reduces care dependence in severely demented patients. Copyright © 1999 John Wiley & Sons, Ltd.
International Journal of Geriatric Psychiatry – Wiley
Published: Feb 1, 1999
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.